Clinical Trial Update: A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC [Phase 2]

View source ↗

Summary

A randomized, placebo-controlled, double-blind Phase 2 study evaluating OSI-906 in advanced hepatocellular carcinoma has been terminated. The trial was terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• OSI-906 (OSI-906)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Advanced Hepatocellular Carcinoma (HCC) | Phase 2 | Status: TERMINATED